Treatment-related adverse events were mild, and tolerance was excellent.<h4>Conclusion</h4>For patients with PD-L1-high advanced NSCLC, nivolumab monotherapy can induce deep and durable immune responses, enabling long-term survival with a manageable safety profile, even in elderly patients with multiple comorbidities. The gene discussed is CD274; the disease is non-small cell lung carcinoma.